<DOC>
	<DOC>NCT00044746</DOC>
	<brief_summary>Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.</brief_summary>
	<brief_title>Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<criteria>Inclusion Criteria Patients with diabetes mellitus Inpatient Have 1 or more infected ulcer(s) below the ankle Exclusion Criteria Must not have gangrene or severely impaired arterial supply in your foot Must not have a bone infection in the area of your ulcer Must not have allergies to penicillins</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Diabetes</keyword>
</DOC>